Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

LY3295668

Aliases
LY3295668 Erbumine

2 clinical trials

9 indications

Indication
Neuroblastoma
Indication
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Indication
Stage III Lung Cancer AJCC v8
Indication
Stage IIIA Lung Cancer
Indication
Stage IIIB Lung Cancer
Indication
Lung Cancer
Indication
Stage IV Lung Cancer
Indication
Lung Cancer Stage IVA AJCC v8
Indication
NSCLC
Clinical trial
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2022-04-13
Clinical trial
A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-30